TY - JOUR
T1 - Not Just an Alternative Energy Source
T2 - Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease
AU - Suresh, Varshini V.
AU - Sivaprakasam, Sathish
AU - Bhutia, Yangzom D.
AU - Prasad, Puttur D.
AU - Thangaraju, Muthusamy
AU - Ganapathy, Vadivel
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/4
Y1 - 2025/4
N2 - Ketogenesis, a mitochondrial metabolic pathway, occurs primarily in liver, but kidney, colon and retina are also capable of this pathway. It is activated during fasting and exercise, by “keto” diets, and in diabetes as well as during therapy with SGLT2 inhibitors. The principal ketone body is β-hydroxybutyrate, a widely recognized alternative energy source for extrahepatic tissues (brain, heart, muscle, and kidney) when blood glucose is sparse or when glucose transport/metabolism is impaired. Recent studies have identified new functions for β-hydroxybutyrate: it serves as an agonist for the G-protein-coupled receptor GPR109A and also works as an epigenetic modifier. Ketone bodies protect against inflammation, cancer, and neurodegeneration. HMGCS2, as the rate-limiting enzyme, controls ketogenesis. Its expression and activity are regulated by transcriptional and post-translational mechanisms with glucagon, insulin, and glucocorticoids as the principal participants. Loss-of-function mutations occur in HMGCS2 in humans, resulting in a severe metabolic disease. These patients typically present within a year after birth with metabolic acidosis, hypoketotic hypoglycemia, hepatomegaly, steatotic liver damage, hyperammonemia, and neurological complications. Nothing is known about the long-term consequences of this disease. This review provides an up-to-date summary of the biological functions of ketone bodies with a special focus on HMGCS2 in health and disease.
AB - Ketogenesis, a mitochondrial metabolic pathway, occurs primarily in liver, but kidney, colon and retina are also capable of this pathway. It is activated during fasting and exercise, by “keto” diets, and in diabetes as well as during therapy with SGLT2 inhibitors. The principal ketone body is β-hydroxybutyrate, a widely recognized alternative energy source for extrahepatic tissues (brain, heart, muscle, and kidney) when blood glucose is sparse or when glucose transport/metabolism is impaired. Recent studies have identified new functions for β-hydroxybutyrate: it serves as an agonist for the G-protein-coupled receptor GPR109A and also works as an epigenetic modifier. Ketone bodies protect against inflammation, cancer, and neurodegeneration. HMGCS2, as the rate-limiting enzyme, controls ketogenesis. Its expression and activity are regulated by transcriptional and post-translational mechanisms with glucagon, insulin, and glucocorticoids as the principal participants. Loss-of-function mutations occur in HMGCS2 in humans, resulting in a severe metabolic disease. These patients typically present within a year after birth with metabolic acidosis, hypoketotic hypoglycemia, hepatomegaly, steatotic liver damage, hyperammonemia, and neurological complications. Nothing is known about the long-term consequences of this disease. This review provides an up-to-date summary of the biological functions of ketone bodies with a special focus on HMGCS2 in health and disease.
KW - GPR109A
KW - HMGCS2
KW - cancer
KW - epigenetic modification
KW - inflammation
KW - ketoacidosis
KW - ketone body transporters
KW - loss-of-function mutations
KW - neurodegeneration
KW - β-hydroxybutyrate
UR - http://www.scopus.com/inward/record.url?scp=105003594303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105003594303&partnerID=8YFLogxK
U2 - 10.3390/biom15040580
DO - 10.3390/biom15040580
M3 - Review article
C2 - 40305364
AN - SCOPUS:105003594303
SN - 2218-273X
VL - 15
JO - Biomolecules
JF - Biomolecules
IS - 4
M1 - 580
ER -